- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.
EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities
EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy
EP: 5.Examining Trial Data on Omaveloxolone Efficacy
EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia
EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape
EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia
EP: 9.Diagnosis of Friedreich Ataxia
EP: 10.Impact of Friedreich Ataxia on Quality of Life
EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale
EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia
EP: 13.Challenges Associated With Friedreich Ataxia
EP: 14.Future Considerations for Friedreich Ataxia
- What are some of the key recommendations outlined in the guidelines for managing FA published in November 2022?
- Could you elaborate on the significance of omaveloxolone as the first FDA-approved therapy for Friedreich’s ataxia and how you incorporate this treatment into your disease management regimen? Since the approval of omaveloxolone, what has been the impact on the management of advanced stages of the disease and life expectancy in FA patients?
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More
